Evaluation of Fluticasone Propionate and Fluticasone Propionate/Salmeterol Combination on Exercise in Pediatric and Adolescent Patients with Asthma

Table 1: Baseline Subject Demographic and Pulmonary Function Characteristics

	FSC 100/50	FP 100
Number	113	118
Age, years	11.4 ± 3.42	11.7 ± 3.43
Gender, Female % / Male %	42 / 58	44 / 56
Ethnic Origin, % White Black Hispanic Asian Other	55 29 15 <1 0	52 33 9 3 3
Height, cm	150.0 ± 18.11	150.9 ± 17.88
Weight, kg	49.49 ± 19.62	51.7 ± 19.155
ICS total daily dose prior to study, mcg	195.4 ± 114.33	212.0 ± 114.97
FEV₁, L	2.17 ± 0.696	2.19 ± 0.703
FEV₁ % predicted	83.4 ± 6.61	83.5 ± 6.56
% Reversibility	14.5 ± 15.75	11.8 ± 9.50
PEF, L/second	4.55 ± 1.577	4.61 ± 1.633
PEF, % predicted	77.4 ± 14.72	78.1 ± 14.55

Gender and Ethnic Origin expressed as %; all other data expressed as mean ± standard deviation.Statistical testing was not performed on baseline characteristics.